1.On May 12, the DPRK reported for the first time that there were cases of Omicron virus infection in China. With the increasing number of fever cases, the import and export trade of traditional Chinese medicine will also be directly impacted.
Through recent research on the four major drug markets, our platform found that the varieties of North Korean related medicinal materials, such as cuttlebone, North bean root, white fresh skin, white Wei, Ligusticum, pangshanlong, etc., have increased in varying degrees in the past week, and some varieties have even increased by more than 50%.
2.Antidepressant TOP10 is out! 1.8 billion varieties lead the rise of domestic brands.
Recently, the news of phase III clinical success came from two antidepressants. According to the data of Intranet, in 2021, the sales of terminal antidepressants and chemical drugs in China’s public medical institutions exceeded 8.7 billion yuan; Pfizer won the leading position for the first time, and Jingwei pharmaceutical entered the top three for the first time; Escitalopram oxalate tablets topped the list again and again. The sales of agomelatine tablets rose by 72.74%, and the sales of centralized varieties fell sharply. 20 varieties have been evaluated, and Fosun, Kelun and Huahai have led the list; 12 class 1 new drugs are under development, involving LVYE, hausen, xinlitai, etc.
3.The 26billion blood lipid lowering drug market fell, and PCSK9 antibody, the target of medical insurance, became stronger
With the emergence of new drugs all over the world, China’s hypolipidemic drug market is changing. According to the data of Intranet, in 2019, the market scale of terminal hypolipidemic drugs in China’s public medical institutions exceeded 26billion yuan. However, with the over evaluation of the four statins and the full implementation of the national centralized purchase, the price of blood lipid lowering drugs has shown a trend of price reduction.
4.The new 2billion varieties of oral hypoglycemic drug king “change of ownership” were born. In recent years, with the aging of the population and the gradual increase of the incidence rate of chronic diseases, the related drug market has attracted much attention. According to MI Nei’s data, in 2021, the market sales scale of terminal oral diabetes chemical drugs in China’s public medical institutions exceeded the level of 20billion yuan. Among the top10 products, the centralized purchase products occupy 6 seats, and the sales of 8 products exceed 1billion yuan. Metformin hydrochloride tablets have ascended the “first brother” throne, and dagliejing tablets have exceeded 2billion yuan for the first time, reaching the top three. Since this year, 8 oral hypoglycemic drugs have been approved for marketing. At present, 37 oral hypoglycemic drugs (more than 150 acceptance numbers) are under review, among which dagliejing tablets, weigliptin tablets and sitagliptin phosphate tablets are the most popular; No generic drugs have been approved for the six products, including kaglitazone metformin sustained-release tablets, rubiprostone capsules, and tegagliptin hydrobromide tablets, which involve many enterprises, such as Sichuan Kelun pharmaceutical, Nanjing Zhengda Tianqing pharmaceutical, Lepu pharmaceutical, etc.
5.CDC issued monkeypox health tips: there is no risk of infection among the general population in China.
According to the official wechat official account of CDC, since May 2022, a large number of monkeypox cases have been found in some countries in non endemic areas, and interpersonal transmission has occurred. In order to protect the health of Chinese citizens, CDC has put forward relevant health tips. Among them, monkeypox is a self limiting disease, and most of them have a good prognosis. At present, there is no specific anti monkeypox drug in China. There is no monkeypox case report in China, and monkeypox virus has not been found in wild animals or in entry quarantine. The general population has no risk of infection.
6.The technical characteristics and advantages of tumor tissue culture drug sensitivity assay (HDRA).
The tumor tissue culture drug sensitivity assay (HDRA) within the scope of NCCN guidelines realizes the combination of standardized treatment and personalization, optimizes the guidelines, reduces postoperative recurrence of tumor patients and prolongs survival.
7.The cephalosporin market has fallen through the 57billion Chengdu Beite new 1billion echelon!
Cephalosporins are commonly used in clinical medicine and the Top1 sub category of systemic anti-bacterial drugs. In recent years, cephalosporins have also become a “frequent customer” of national centralized procurement. Under the influence of multiple policies, the sales scale of cephalosporins in the terminals of public medical institutions in China fell again in 2021, falling below 57billion yuan. The sales of injections have recovered and their proportion has increased. The pattern of many enterprises of domestic varieties that have entered the national collection has changed dramatically. The generic drug market is speeding up “vacating space”; In recent years, the R & D direction of domestic pharmaceutical enterprises has focused on the new dosage forms of compound preparations and powder liquid double chamber bags, and a number of potential new products are ready to go.
JinDun Medical has long-term scientific research cooperation and technology grafting with Chinese universities. With Jiangsu’s rich medical resources, it has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. It also provides market and sales services in the whole process from intermediate to finished product API. Utilize the accumulated resources of Yangshi Chemical in fluorine chemistry to provide special chemical customization services for partners. Provide process innovation and impurity research services to target customers.
Post time: Nov-10-2022